Complement Activation Products and Cytokines in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
02 11 2020
Historique:
entrez: 30 11 2020
pubmed: 1 12 2020
medline: 8 5 2021
Statut: ppublish

Résumé

To investigate the characteristics of complement activation products and angiogenic cytokines in the aqueous humor in eyes with pachychoroid neovasculopathy (PNV) and neovascular age-related macular degeneration (nAMD). This was a prospective, comparative, observational study. All patients with choroidal neovascularization were classified as PNV without polyps, PNV with polyps (polypoidal choroidal vasculopathy [PCV]), or drusen-associated nAMD according to the presence or absence of pachychoroid features and soft drusen. This study included a total of 105 eyes. Aqueous humor samples were collected from 25 eyes with PNV without polyps, 23 eyes with PCV, and 24 eyes with drusen-associated nAMD before intravitreal anti-vascular endothelial growth factor (VEGF) injection and cataract surgery in 33 control eyes. Clinical samples were measured for complement component 3a (C3a), C4a, C5a, VEGF, and macrophage chemoattractant protein 1 (MCP-1) using a bead-based immunoassay. C3a and MCP-1 levels were significantly higher in PCV (P = 0.032 and P = 0.039, respectively) and drusen-associated nAMD (P = 0.01 for both comparisons) than in controls, and no difference was seen in C3a and MCP-1 levels between PNV and controls (P = 0.747 and P = 0.294, respectively). VEGF levels were significantly higher in PNV (P = 0.016), PCV (P = 0.009), and drusen-associated nAMD (P = 0.043) than in controls. In PNV, the VEGF levels elevated without elevated C3a and MCP-1. PNV, PCV, and drusen-associated nAMD had significantly distinct profiles of complement activation products and cytokines in the aqueous humor.

Identifiants

pubmed: 33252634
pii: 2772004
doi: 10.1167/iovs.61.13.39
pmc: PMC7705396
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Cytokines 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

39

Références

Ophthalmic Res. 2020;63(3):252-258
pubmed: 31645047
Retina. 2015 Jan;35(1):1-9
pubmed: 25158945
Ophthalmology. 2009 Dec;116(12):2393-9
pubmed: 19815292
Mol Vis. 2012;18:574-80
pubmed: 22419849
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):376-382
pubmed: 30682207
Biomed Res Int. 2016;2016:6958752
pubmed: 27747237
Immun Ageing. 2016 Feb 16;13:4
pubmed: 26884800
Science. 2005 Apr 15;308(5720):421-4
pubmed: 15761121
Jpn J Ophthalmol. 2020 Jul;64(4):323-337
pubmed: 32318919
Eye (Lond). 2019 Dec;33(12):1859-1864
pubmed: 31267090
PLoS One. 2016 Jan 22;11(1):e0147346
pubmed: 26799405
Prog Retin Eye Res. 2016 Jan;50:1-24
pubmed: 26307399
Science. 2005 Apr 15;308(5720):385-9
pubmed: 15761122
Clin Exp Ophthalmol. 2018 Aug;46(6):661-669
pubmed: 29360187
Sci Rep. 2019 Dec 19;9(1):19447
pubmed: 31857597
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):292-298
pubmed: 28114590
Arch Ophthalmol. 2005 Nov;123(11):1570-4
pubmed: 16286620
Retina. 2013 Oct;33(9):1809-14
pubmed: 23492946
Mol Immunol. 2009 Sep;46(14):2753-66
pubmed: 19477527
Sci Rep. 2018 Jun 26;8(1):9679
pubmed: 29946065
Trans Am Ophthalmol Soc. 1977;75:180-254
pubmed: 613523
Retina. 1990;10(1):1-8
pubmed: 1693009
Arch Ophthalmol. 2007 Jan;125(1):55-62
pubmed: 17210852
Sci Rep. 2018 Jul 12;8(1):10520
pubmed: 30002400
Arch Ophthalmol. 2004 Apr;122(4):477-85
pubmed: 15078664
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2328-33
pubmed: 16452172
Mol Diagn Ther. 2006;10(5):303-10
pubmed: 17022693
Diabetologia. 1999 Jul;42(7):870-7
pubmed: 10440131
Eye (Lond). 2017 May;31(5):810-813
pubmed: 28128795
Arch Ophthalmol. 2010 Oct;128(10):1281-6
pubmed: 20937997
Br J Ophthalmol. 2018 Apr;102(4):448-454
pubmed: 28765149
Eye (Lond). 1997;11 ( Pt 4):515-22
pubmed: 9425418
Mol Vis. 2009 Sep 19;15:1906-14
pubmed: 19784389
Nat Genet. 2006 Apr;38(4):458-62
pubmed: 16518403
Eye (Lond). 2019 Jan;33(1):14-33
pubmed: 29995841
Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5924-5931
pubmed: 30551200
BMC Ophthalmol. 2020 Jan 8;20(1):15
pubmed: 31914968
Sci Rep. 2017 Mar 27;7:45081
pubmed: 28345626
Ophthalmology. 2009 Feb;116(2):304-10
pubmed: 19187823
Ophthalmologica. 2019;241(2):81-89
pubmed: 30048978
Acta Ophthalmol. 2020 Jun;98(4):384-389
pubmed: 31680415
Exp Eye Res. 2020 Jun;195:108025
pubmed: 32224205
Ophthalmic Res. 2015;53(1):2-7
pubmed: 25472810

Auteurs

Yutaka Kato (Y)

Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.

Yasuharu Oguchi (Y)

Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.

Tomoko Omori (T)

Department of Immunology, Fukushima Medical University, Fukushima, Japan.

Hiroaki Shintake (H)

Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.

Ryutaro Tomita (R)

Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.

Akihito Kasai (A)

Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.

Masashi Ogasawara (M)

Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.

Yukinori Sugano (Y)

Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.

Kanako Itagaki (K)

Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.

Akira Ojima (A)

Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.

Takeshi Machida (T)

Department of Immunology, Fukushima Medical University, Fukushima, Japan.

Hideharu Sekine (H)

Department of Immunology, Fukushima Medical University, Fukushima, Japan.

Tetsuju Sekiryu (T)

Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH